Trial Update November 12, 2026

TB-500 Trial for Cardiovascular Biomarkers Now Recruiting

A clinical trial listing update for TB-500, also known as Thymosin Beta 4 17-23 Fragment, was recorded on November 12, 2026. The study is titled "TB-500 (Thymosin Beta 4 17-23 Fragment) for Cardiovascular Biomarkers in Stable ASCVD." It is registered under identifier NCT07487363 and is listed as Phase 1/Phase 2.

According to the registry entry, the trial's current status is recruiting. The study focuses on cardiovascular biomarkers in individuals with stable atherosclerotic cardiovascular disease, or ASCVD. No results have been posted for this trial at this time.

TB-500 remains classified as an unapproved compound used only in research settings. It has no approved medical indication. This update reflects only the trial's registration status and phase classification as listed on ClinicalTrials.gov. No outcome data, efficacy claims, or safety findings are included in this update, since none have been reported in the registry record.

Readers interested in background on this peptide can consult the compound overview for additional context.

See the full tb-500 overview

Source: https://clinicaltrials.gov/study/NCT07487363